ArticleEClinicalMedicine2023

Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).

Wensi Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.